Johnson & Johnson (NYSE:JNJ) Price Target Raised to $232.00 at Leerink Partners

Johnson & Johnson (NYSE:JNJ) had its price target hoisted by equities researchers at Leerink Partners from $201.00 to $232.00 in a research note issued on Thursday,MarketScreener reports. The firm currently has a “market perform” rating on the stock. Leerink Partners’ target price points to a potential upside of 5.44% from the stock’s previous close.

A number of other research firms also recently weighed in on JNJ. Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a research note on Thursday. Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 22nd. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective on the stock in a research report on Monday, October 20th. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. Finally, Raymond James Financial upped their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $224.82.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded up $1.55 on Thursday, reaching $220.04. 570,586 shares of the stock were exchanged, compared to its average volume of 9,340,856. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a market cap of $530.13 billion, a PE ratio of 19.92, a P/E/G ratio of 2.24 and a beta of 0.34. The firm’s 50 day moving average is $207.86 and its 200-day moving average is $188.48. Johnson & Johnson has a one year low of $141.50 and a one year high of $222.17.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, meeting the consensus estimate of $2.46. The business had revenue of $24.56 billion during the quarter, compared to the consensus estimate of $24.14 billion. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. The company’s revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the business earned $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds and other institutional investors have recently bought and sold shares of JNJ. Dara Capital US Inc. bought a new stake in Johnson & Johnson in the 4th quarter valued at about $581,000. Colorado Capital Management Inc. lifted its holdings in shares of Johnson & Johnson by 6.7% in the 4th quarter. Colorado Capital Management Inc. now owns 2,370 shares of the company’s stock worth $490,000 after purchasing an additional 149 shares in the last quarter. Ariston Services Group grew its position in Johnson & Johnson by 36.0% in the 4th quarter. Ariston Services Group now owns 2,258 shares of the company’s stock valued at $467,000 after purchasing an additional 598 shares during the period. Brown Lisle Cummings Inc. raised its holdings in Johnson & Johnson by 3.7% during the fourth quarter. Brown Lisle Cummings Inc. now owns 13,582 shares of the company’s stock worth $2,811,000 after buying an additional 484 shares during the last quarter. Finally, Successful Portfolios LLC grew its holdings in shares of Johnson & Johnson by 11.0% during the fourth quarter. Successful Portfolios LLC now owns 5,066 shares of the company’s stock valued at $1,035,000 after buying an additional 501 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 beat and raised 2026 outlook — JNJ topped earnings and revenue estimates, reported stronger organic growth and issued 2026 guidance that management says should exceed Street expectations, supporting bullish sentiment. JNJ Tops Q4 Earnings
• Positive Sentiment: Analyst upgrades and higher targets — Several firms raised price targets (notably Scotiabank to $265) and the consensus broker view is skewed toward buy/moderate buy, which supports further upside. Scotiabank Raises JNJ Target
• Positive Sentiment: Dividend credibility and cash returns — J&J’s Dividend King status (63+ years of raises), healthy payout ratio and buyback capacity keep income investors supportive. Dividend King Analysis
• Neutral Sentiment: Technical setup — Analysts/market outlets note a trend‑following buy signal after the post‑earnings pullback, which can attract momentum flows but is dependent on macro/sector breadth. MarketBeat Technical Note
• Neutral Sentiment: Media and TV endorsements — Positive commentary from high‑profile commentators (e.g., Jim Cramer) may underpin short‑term interest but has limited fundamental impact. Jim Cramer on JNJ
• Negative Sentiment: Talc litigation advances — A court decision cleared the way for plaintiffs’ expert testimony in the talc MDL, a legal overhang that can resume volatility and possible liability risk. Talc Litigation Update
• Negative Sentiment: Stelara biosimilar pressure — Loss of Stelara patent protection and accelerating biosimilar competition dented prior sales and remain a medium‑term headwind for revenue mix. Stelara Biosimilar Headwind
• Negative Sentiment: Drug‑pricing deal cost — Management flagged “hundreds of millions” of costs tied to a recent drug‑pricing agreement, which modestly offsets EPS upside in 2026. Guidance & Pricing Headwind

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.